Immunovia AB Announces New Nomination Committee for Upcoming AGM in 2025

Immunovia AB (Publ), a prominent name in the pancreatic cancer diagnostics field, has officially announced the formation of its Nomination Committee ahead of the 2025 Annual General Meeting (AGM). This strategic move is essential for ensuring that the board is composed of individuals with the right skills and experience as the company transitions from a focus on research and development to commercialization, particularly in the U.S. market.

According to the guidelines set forth for the Nomination Committee, it comprises four members. Three of these members are appointed by the company's three largest shareholders based on voting power, while the fourth member is the Chair of the Board of Directors. The appointed members include:
- Christer Køhler, representing Jens Henrik Jensen
- Mats Leifland, representing Vincent Saldell
- Sara Ek, representing Carl Borrebaeck
- Peter Høngaard Andersen, serving as the Chair of the Board

Together, these members represent approximately 5.65% of the total shares and votes in Immunovia as of September 30, 2024. Jeff Borcherding, the CEO of Immunovia and a significant shareholder, decided against appointing a representative to maintain the independence of the committee.

The Nomination Committee's primary responsibility is to prepare recommendations for the AGM, slated for May 14, 2025. This includes naming candidates for the Board of Directors and suggesting appropriate compensation structures to ensure competitiveness and fairness. Additionally, the committee will evaluate and recommend the election and compensation of the company's auditors, which is a critical function for oversight.

Peter Høngaard Andersen, Chair of the Board of Directors, expressed enthusiasm regarding the formation of the committee, stating, “It is a pleasure to have the Nomination Committee in place to start the work leading up to the AGM 2025. It is of vital importance that the competencies of Immunovia's board members reflect the transition of the company's focus from research and development to commercialization in the U.S.”

This announcement comes at a time when Immunovia is actively working towards increasing survival rates for pancreatic cancer patients through early detection methods. The company is dedicated to developing and commercializing blood tests that can identify proteins and antibodies indicative of pancreatic cancer in high-risk individuals. Moreover, Immunovia is collaborating with healthcare professionals, leading experts, and patient advocacy groups to expand the accessibility of their tests for those who are most vulnerable.

In the U.S. alone, it is estimated that about 1.8 million people are at high risk for pancreatic cancer, making the market for this diagnostic testing significant. Immunovia's shares are listed under the ticker IMMNOV on Nasdaq Stockholm, highlighting their public standing and commitment to advancing cancer diagnostics.

As the company gears up for its AGM and seeks to solidify its board with qualified candidates, stakeholders and the public will be watching closely. The Nomination Committee's decisions will play a pivotal role in shaping the direction and governance of Immunovia AB as it strives for impactful contributions in the fight against pancreatic cancer.

For further information, stakeholders may access additional details on the Nomination Committee via Immunovia’s official governance page. Such strategic appointments suggest a proactive approach towards corporate governance, which is imperative for fostering growth and innovation in this vital healthcare sector.